{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-093694","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.912042+00:00","generated_at":"2026-06-23T21:53:40.044488+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Innoviva files risk factor update with no specific new disclosure","bullets":["Filed an 8-K to supplement risk factors from its June 30, 2022 10-Q and 2021 10-K.","Updated risk factors cover clinical trial failure, patient enrollment delays, and third-party dependence.","No specific new events, financial results, or business developments were reported.","The risk factor language is standard biotech boilerplate with no material changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-093694","json":"https://secwatch.observer/filing/0001104659-22-093694.json","markdown":"https://secwatch.observer/filing/0001104659-22-093694.md","text":"https://secwatch.observer/filing/0001104659-22-093694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922093694/0001104659-22-093694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922093694/tm2224315d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:53:40.044488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}